human vascular smooth muscle cells Search Results


90
Innoprot Inc human brain vascular smooth muscle cells hbvsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Hbvsmcs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/Human+Brain+Vascular+Smooth+Muscle+Cells/pmc08444498-129-3-13
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells hbvsmcs - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
ScienCell human brain vascular smooth muscle cells sciencell research
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Sciencell Research, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+brain+vascular+smooth+muscle+cells+sciencell+research/10__1074_slash_jbc__m110__127738-161-0-11
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells sciencell research - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BioWhittaker Molecular Applications human aortic vascular smooth muscle cells (havsms)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Aortic Vascular Smooth Muscle Cells (Havsms), supplied by BioWhittaker Molecular Applications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+aortic+vascular+smooth+muscle+cells/pmc04337887-50-0-22
Average 90 stars, based on 1 article reviews
human aortic vascular smooth muscle cells (havsms) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Kurabo industries human aortic smooth muscle cells (smcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Aortic Smooth Muscle Cells (Smcs, supplied by Kurabo industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+aortic+vascular+smooth+muscle+cells/10__1161_slash_atvbaha__107__151829-35-0-6
Average 90 stars, based on 1 article reviews
human aortic smooth muscle cells (smcs - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
ScienCell human brain vascular smooth muscle cells
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+brain+vascular+smooth+muscle+cells/pmc08673708-76-0-9
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
ScienCell human vascular smooth muscle cells (hvsmcs)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Vascular Smooth Muscle Cells (Hvsmcs), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+vascular+smooth+muscle+cells++hvsmcs+/10__1089_slash_ten__tea__2012__0768-200-2-7
Average 90 stars, based on 1 article reviews
human vascular smooth muscle cells (hvsmcs) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
BioWhittaker Molecular Applications human pulmonary vascular smooth muscle cells
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Pulmonary Vascular Smooth Muscle Cells, supplied by BioWhittaker Molecular Applications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+pulmonary+vascular+smooth+muscle+cells/10__1074_slash_jbc__m502088200-44-0-27
Average 90 stars, based on 1 article reviews
human pulmonary vascular smooth muscle cells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
ScienCell human brain vascular smooth muscle cells hbvsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Hbvsmcs, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+brain+vascular+smooth+muscle+cells++hbvsmcs++catalog++1100/pm40456777-346-0-7
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells hbvsmcs - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Bioarray Inc human vascular smooth muscle cells (hsmcs)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Vascular Smooth Muscle Cells (Hsmcs), supplied by Bioarray Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+vascular+smooth+muscle+cells++hsmcs+/pmc08145910-97-72-82
Average 90 stars, based on 1 article reviews
human vascular smooth muscle cells (hsmcs) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
ScienCell human aortic vascular smooth muscle cells (vsmcs)
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Aortic Vascular Smooth Muscle Cells (Vsmcs), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+aortic+vascular+smooth+muscle+cells++vsmcs+/pmc03248008-43-0-12
Average 90 stars, based on 1 article reviews
human aortic vascular smooth muscle cells (vsmcs) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare human aortic vascular smooth muscle cells
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Aortic Vascular Smooth Muscle Cells, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+aortic+vascular+smooth+muscle+cells/pm39929946-27-36-7
Average 90 stars, based on 1 article reviews
human aortic vascular smooth muscle cells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
China Center for Type Culture Collection human aortic vascular smooth muscle cells t/g havsmcs (havsmcs)
The α -SMA and SIRT7 expression in ox-LDL-treated <t>HAVSMCs.</t> (a) Immunofluorescence staining was used to detect α -SMA in HAVSMCs stimulated with ox-LDL. Nuclei were stained with DAPI (blue), 200× magnification. (b) The protein expression level of α -SMA was measured by Western blot. ∗∗∗ P < 0.001 versus <t>VSMCs.</t> The protein level of SIRT7 was measured by Western blot (c) and RT-qPCR (d) in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 versus VSMCs. The expression level of SIRT7 was measured by Western blot (e) and RT-qPCR (f) after silencing of SIRT7 in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus VSMCs; # P < 0.05 and ## P < 0.01 versus siRNA-NC. The expression level of SIRT7 was measured by Western blot (g) and RT-qPCR (h) after overexpression of SIRT7 in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus VSMCs; ## P < 0.01 and ### P < 0.001 versus Vector-NC.
Human Aortic Vascular Smooth Muscle Cells T/G Havsmcs (Havsmcs), supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vascular+smooth+muscle+cells/human+aortic+vascular+smooth+muscle+cells+t+g+havsmcs++havsmcs+/pmc06304541-35-2-13
Average 90 stars, based on 1 article reviews
human aortic vascular smooth muscle cells t/g havsmcs (havsmcs) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Journal: Acta Neuropathologica Communications

Article Title: MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

doi: 10.1186/s40478-021-01257-9

Figure Lengend Snippet: MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Article Snippet: Primary cultures of human brain vascular smooth muscle cells (HBVSMCs) were obtained from Innoprot (Derio, Bizkaia, Spain).

Techniques: Expressing, Immunocytochemistry, Western Blot, Transfection

The α -SMA and SIRT7 expression in ox-LDL-treated HAVSMCs. (a) Immunofluorescence staining was used to detect α -SMA in HAVSMCs stimulated with ox-LDL. Nuclei were stained with DAPI (blue), 200× magnification. (b) The protein expression level of α -SMA was measured by Western blot. ∗∗∗ P < 0.001 versus VSMCs. The protein level of SIRT7 was measured by Western blot (c) and RT-qPCR (d) in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 versus VSMCs. The expression level of SIRT7 was measured by Western blot (e) and RT-qPCR (f) after silencing of SIRT7 in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus VSMCs; # P < 0.05 and ## P < 0.01 versus siRNA-NC. The expression level of SIRT7 was measured by Western blot (g) and RT-qPCR (h) after overexpression of SIRT7 in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus VSMCs; ## P < 0.01 and ### P < 0.001 versus Vector-NC.

Journal: BioMed Research International

Article Title: SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/ β -Catenin Signaling Pathway

doi: 10.1155/2018/4769596

Figure Lengend Snippet: The α -SMA and SIRT7 expression in ox-LDL-treated HAVSMCs. (a) Immunofluorescence staining was used to detect α -SMA in HAVSMCs stimulated with ox-LDL. Nuclei were stained with DAPI (blue), 200× magnification. (b) The protein expression level of α -SMA was measured by Western blot. ∗∗∗ P < 0.001 versus VSMCs. The protein level of SIRT7 was measured by Western blot (c) and RT-qPCR (d) in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 versus VSMCs. The expression level of SIRT7 was measured by Western blot (e) and RT-qPCR (f) after silencing of SIRT7 in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus VSMCs; # P < 0.05 and ## P < 0.01 versus siRNA-NC. The expression level of SIRT7 was measured by Western blot (g) and RT-qPCR (h) after overexpression of SIRT7 in ox-LDL-treated HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus VSMCs; ## P < 0.01 and ### P < 0.001 versus Vector-NC.

Article Snippet: The human aortic vascular smooth muscle cells T/G HAVSMCs (HAVSMCs) were obtained from China Center for Type Culture Collection (Wuhan, China) and maintained in DMEM medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 μ g/ml penicillin, and 100 μ g/ml streptomycin at 37°C in a 5% CO 2 humidified incubator.

Techniques: Expressing, Immunofluorescence, Staining, Western Blot, Quantitative RT-PCR, Over Expression, Plasmid Preparation

(a) The level of α -SMA after SIRT7 silencing or overexpression in ox-LDL-treated HAVSMCs was measured by immunofluorescence staining. Nuclei were stained with DAPI (blue), 200× magnification. (b) The protein expression level of α -SMA after SIRT7 silencing (b) or overexpression (c) in ox-LDL-treated HAVSMCs was assessed by Western blot. ∗ P < 0.05 and ∗∗ P < 0.01 versus VSMCs; # P < 0.05 versus siRNA-NC or Vector-NC.

Journal: BioMed Research International

Article Title: SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/ β -Catenin Signaling Pathway

doi: 10.1155/2018/4769596

Figure Lengend Snippet: (a) The level of α -SMA after SIRT7 silencing or overexpression in ox-LDL-treated HAVSMCs was measured by immunofluorescence staining. Nuclei were stained with DAPI (blue), 200× magnification. (b) The protein expression level of α -SMA after SIRT7 silencing (b) or overexpression (c) in ox-LDL-treated HAVSMCs was assessed by Western blot. ∗ P < 0.05 and ∗∗ P < 0.01 versus VSMCs; # P < 0.05 versus siRNA-NC or Vector-NC.

Article Snippet: The human aortic vascular smooth muscle cells T/G HAVSMCs (HAVSMCs) were obtained from China Center for Type Culture Collection (Wuhan, China) and maintained in DMEM medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 μ g/ml penicillin, and 100 μ g/ml streptomycin at 37°C in a 5% CO 2 humidified incubator.

Techniques: Over Expression, Immunofluorescence, Staining, Expressing, Western Blot, Plasmid Preparation

The effects of SIRT7 knockdown, overexpression, or treatment with DKK-1 on HAVSMCs proliferation stimulated by ox-LDL. (a) CCK-8 cell proliferation assay. ### P < 0.001 versus siRNA-NC; △ P < 0.05 and △△△ P < 0.001 versus Vector-NC; ∗ P < 0.05 versus Vector-SIRT7. (b) Cell cycle distribution (%) in G1, S, and G2 phases. # P < 0.05 and ### P < 0.001 versus siRNA-NC; △△ P < 0.01 and △△△ P < 0.001 versus Vector-NC; ∗ P < 0.05 versus Vector-SIRT7. (c) Cell cycle analysis.

Journal: BioMed Research International

Article Title: SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/ β -Catenin Signaling Pathway

doi: 10.1155/2018/4769596

Figure Lengend Snippet: The effects of SIRT7 knockdown, overexpression, or treatment with DKK-1 on HAVSMCs proliferation stimulated by ox-LDL. (a) CCK-8 cell proliferation assay. ### P < 0.001 versus siRNA-NC; △ P < 0.05 and △△△ P < 0.001 versus Vector-NC; ∗ P < 0.05 versus Vector-SIRT7. (b) Cell cycle distribution (%) in G1, S, and G2 phases. # P < 0.05 and ### P < 0.001 versus siRNA-NC; △△ P < 0.01 and △△△ P < 0.001 versus Vector-NC; ∗ P < 0.05 versus Vector-SIRT7. (c) Cell cycle analysis.

Article Snippet: The human aortic vascular smooth muscle cells T/G HAVSMCs (HAVSMCs) were obtained from China Center for Type Culture Collection (Wuhan, China) and maintained in DMEM medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 μ g/ml penicillin, and 100 μ g/ml streptomycin at 37°C in a 5% CO 2 humidified incubator.

Techniques: Knockdown, Over Expression, CCK-8 Assay, Proliferation Assay, Plasmid Preparation, Cell Cycle Assay

The effects of SIRT7 knockdown, overexpression, or treatment with DKK-1 on HAVSMCs migration stimulated by ox-LDL. (a) Images of the migration of HAVSMCs at 0 and 24 h (4× magnification). (b) The wound closure of ox-LDL treatment groups at 0 and 24 h. ### P < 0.001 versus siRNA-NC; △△△ P < 0.001 versus Vector-NC; ∗∗ P < 0.01 versus Vector-SIRT7.

Journal: BioMed Research International

Article Title: SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/ β -Catenin Signaling Pathway

doi: 10.1155/2018/4769596

Figure Lengend Snippet: The effects of SIRT7 knockdown, overexpression, or treatment with DKK-1 on HAVSMCs migration stimulated by ox-LDL. (a) Images of the migration of HAVSMCs at 0 and 24 h (4× magnification). (b) The wound closure of ox-LDL treatment groups at 0 and 24 h. ### P < 0.001 versus siRNA-NC; △△△ P < 0.001 versus Vector-NC; ∗∗ P < 0.01 versus Vector-SIRT7.

Article Snippet: The human aortic vascular smooth muscle cells T/G HAVSMCs (HAVSMCs) were obtained from China Center for Type Culture Collection (Wuhan, China) and maintained in DMEM medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 μ g/ml penicillin, and 100 μ g/ml streptomycin at 37°C in a 5% CO 2 humidified incubator.

Techniques: Knockdown, Over Expression, Migration, Plasmid Preparation

The protein expression levels of Wnt, β -catenin, and cyclin D1. (a) The protein expression levels of Wnt, β -catenin, and cyclin D1 in SIRT7 knockdown HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus ox-LDL-VSMC; ## P < 0.01 and ### P < 0.001 versus siRNA-NC. (b) The protein expression levels of Wnt, β -catenin, and cyclin D1 in SIRT7 overexpression on HAVSMCs. ∗∗∗ P < 0.001 versus ox-LDL-VSMC; ### P < 0.001 versus Vector-NC.

Journal: BioMed Research International

Article Title: SIRT7 Regulates the Vascular Smooth Muscle Cells Proliferation and Migration via Wnt/ β -Catenin Signaling Pathway

doi: 10.1155/2018/4769596

Figure Lengend Snippet: The protein expression levels of Wnt, β -catenin, and cyclin D1. (a) The protein expression levels of Wnt, β -catenin, and cyclin D1 in SIRT7 knockdown HAVSMCs. ∗∗ P < 0.01 and ∗∗∗ P < 0.001 versus ox-LDL-VSMC; ## P < 0.01 and ### P < 0.001 versus siRNA-NC. (b) The protein expression levels of Wnt, β -catenin, and cyclin D1 in SIRT7 overexpression on HAVSMCs. ∗∗∗ P < 0.001 versus ox-LDL-VSMC; ### P < 0.001 versus Vector-NC.

Article Snippet: The human aortic vascular smooth muscle cells T/G HAVSMCs (HAVSMCs) were obtained from China Center for Type Culture Collection (Wuhan, China) and maintained in DMEM medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 μ g/ml penicillin, and 100 μ g/ml streptomycin at 37°C in a 5% CO 2 humidified incubator.

Techniques: Expressing, Knockdown, Over Expression, Plasmid Preparation